Company intelligence / Profile preview

Aptorum Group Limited

Ownership: Public · APM
Development stage: Phase 1

Overview

A clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs[1][2]

Industry: Biotech

Drug pipeline

5 assets

SACT-1

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $5.2M
Total revenue: $0
Enterprise value: $6.9M

Beyond the preview

Go deeper on Aptorum Group Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptorum Group Limited.

Explore the full profile